

Members of Lumitos board and management team intend to exercise warrants of series T06

Members of the board and management that hold warrants of series T06 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand.

The board and management team intends to exercise warrants, directly or via companies, according to the following:

- Kerstin Jakobsson (Chair of the Board) – 75,000 warrants of series T06, corresponding to approximately SEK 29 thousand
- Marcus Åström (Board Member) – 400,000 warrants of series T06, corresponding to approximately SEK 156 thousand
- Mattias Lundin (Board Member) – 33,332 warrants of series T06, corresponding to approximately SEK 13 thousand
- Sanna Wallenborg (CEO) – 67,180 warrants of series T06, corresponding to approximately SEK 26 thousand

The exercise period for warrants of series T06 commenced on November 4, 2024, and continues to and including November 15, 2024. Complete terms for the warrants are available on the Company's website, www.lumito.se.

Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series T06.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Members of Lumitos board and management team intend to exercise warrants of series T06](#)